Products for Research Use Only

LY83583

CAT: 0804-HY-W013386-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-W013386-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
LY83583 is inhibitor of soluble guanylate cyclase (sGC) with the ability to target the cGMP signaling pathway. LY83583 inhibits the kinase activity-related proliferation of tumor cells by inducing the Cdk inhibitor p21. LY83583 can be used for the study of cancers (colorectal cancer, breast cancer and melanoma) and cardiovascular disease[1][2][3][4].
CAS Number
91300-60-6
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
Guanylate Cyclase
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Neurological Disease; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/ly83583.html
Concentration
10mM
Purity
99.84
Solubility
DMSO : 200 mg/mL (ultrasonic)
Smiles
O=C1C=C(NC2=CC=CC=C2)C(C3=C1N=CC=C3)=O
Molecular Formula
C15H10N2O2
Molecular Weight
250.26
Precautions
H315, H319, H335
References & Citations
[1]Lodygin D, et al. Induction of the Cdk inhibitor p21 by LY83583 inhibits tumor cell proliferation in a p53-independent manner. J Clin Invest. 2002 Dec;110 (11) :1717-27. |[2]Kontos HA, et al. Hydroxyl radical-dependent inactivation of guanylate cyclase in cerebral arterioles by methylene blue and by LY83583. Stroke. 1993 Mar;24 (3) :427-34.|[3]Prasad RK, et al. LY-83583 stimulates glucose transporter-1-mediated glucose transport independent of changes in cGMP levels. Eur J Pharmacol. 1999 Jan 29;366 (1) :101-9.|[4]Ribeiro AC, et al. The effects of intracerebroventricular application of 8-Br-cGMP and LY-83,583, a guanylyl cyclase inhibitor, on sleep-wake activity in rats. Brain Res. 2005 Jul 5;1049 (1) :25-33.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported